Sunil Sharma MD

Summary

• I am a Board Certified Medical Oncologist and a physician scientist who specializes in treating gastrointestinal, neuroendocrine and rare tumors like mesotheliomas. My research interests include development of novel early phase clinical trials and discovery of novel anti-cancer therapies esp. those that target the epigenome and other interesting cancer targets.
  My career has been eclectic and I consider myself as a senior academic physician executive with excellent leadership and broad development
  skills, business acumen and track record of success. Here are some of my skills-
  • World – recognized leader in early phase drug development and discovery
  • Instrumental in advancing several drugs (biologics and small molecules) from pre-clinical
  (discovery) evaluation through Phases I-III in oncology and immunology
  • Academic expertise in Program Creation including starting and growing Phase 1 programs and Experimental Therapeutic Programs
  • Leadership of Cancer Centers and PO1 grant filings
  • Developed Cancer centers to Comprehensive status
  • Extensive network for clinical research including Academia, Industry and Cooperative Groups
  • FDA interactions from Phase 1 to Phase 3, IND to NDA filings
  
  I have started many biotechnology companies. These include Beta-Cat Pharmaceuticals (Now Iterion Pharma), Salarius Pharmaceuticals (NSDX:SLRX) and Stingray Pharmaceuticals. I am on the Scientific Advisory Board of many biotechnology companies. I have a MBA from University of Massachusetts- Amherst.
  
  I derive my inspiration from brave souls who face this disease and also from my mother who pioneered the development of oncology in India and was a trailblazer in her time.

Possible New Treatment for Childhood Cancer -- Stephen Lessnick, MD, PhD, and Su
Two heads are better than one, they say-and researchers from Huntsman Cancer Institute (HCI) at the University of Utah have proved it. By combining basic scienc

Sunil Sharma, M.B.A., M.D., FACP
New Treatment Shows 80% Response Rate in a Phase I Clinical Trial, Becomes a "Breakthrough Therapy". Cancer is a complex disease to diagnose and treat. Cancer c

DTRF 2016 Patient Meeting Presentation - Dr. Sunil Sharma, University of Utah, H
Please enable JavaScript to experience Vimeo in all of its glory. Dr. Sunil Sharma speaks about a "New approach to inhibiting beta- catenin." This is Dr. Sharma